Lycia Therapeutics Inc. (LYCA)
NASDAQ: LYCAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LYCA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.72B
- EPS (TTM)
- -$1.04
- Dividend yield
- None
- 52-week range
- 22.19 – 36.49
- Day range
- 31.01 – 34.59
- Volume / Avg
- 422.14K / 432.72K
- Beta
- —
- Shares outstanding
- 52.09M
52-week range
LYCA stock today
Shares of Lycia Therapeutics (LYCA) finished higher on Nov 20 at $33.07, a gain of 4.09% or $1.30 per share, versus the S&P 500's 3.70% decline. Shares are 9.4% below their 52-week high of $36.49, set on Oct 23, 2026 and 49.0% above the 52-week low of $22.19, in the middle of the past year's range. Lycia Therapeutics has posted a net loss over the last twelve months (EPS of -$1.04), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Lycia Therapeutics
Company profileLycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases. The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins. Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Aetna Wun Trombley Ph.D.
- Headquarters
- South San Francisco, CA
- Employees
- 31
- IPO year
- 2026
- Website
- lyciatx.com
LYCA news
All LYCA news- Why is Lycia Therapeutics stock surging today?Investing.com
- Lycia Therapeutics to Present at the 2026 Jefferies Global Healthcare ConferenceGlobeNewswire
- Lycia Shares Fall Nearly 10% After Hours Following $365.1 Mln IPO ClosingNasdaqLYCA, BRK.A
- Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Biotech Stocks On Investor Radar - BOLT +66%, LYCA +33%, LUCD, GMABNasdaqBOLT, GMAB, LUCD, LYCA
Lycia Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MAZEMaze Therapeutics Inc. | 31.37 | -3.27% | $1.72B | vs LYCA |
| REPLReplimune Group Inc. | 19.07 | -0.83% | $1.81B | vs LYCA |
| COAGHemab Therapeutics Holdings Inc. | 39.29 | -1.43% | $1.84B | vs LYCA |
| BCRXBioCryst Pharmaceuticals Inc. | 7.22 | -1.37% | $1.86B | vs LYCA |
| VIRVir Biotechnology Inc. | 8.39 | -5.41% | $1.56B | vs LYCA |
| RXRXRecursion Pharmaceuticals Inc. Class A | 2.45 | -9.93% | $1.53B | vs LYCA |
| ALVOAlvotech | 4.12 | -3.96% | $1.47B | vs LYCA |
| WWBWindward Bio Group AG | 24.29 | +1.15% | $1.45B | vs LYCA |
Indexes, lists and sector
Lycia Therapeutics stock FAQ
What is Lycia Therapeutics's stock price today?
LYCA last traded at $33.07 as of Nov 20, 4:00 PM EST, up 4.09% on the day. Prices are delayed at least 15 minutes.
Who is Lycia Therapeutics's CEO?
Dr. Aetna Wun Trombley Ph.D. is the chief executive officer of Lycia Therapeutics Inc., which has about 31 employees.
What is the LYCA 52-week high?
The 52-week high for LYCA is $36.49 and the 52-week low is $22.19. The stock is currently 9.4% below its high.